Spero Therapeutics, Inc.
SPRO
$2.64
-$0.14-5.04%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 658.86% | -61.65% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 658.86% | -61.65% | |||
| Cost of Revenue | -417.35% | -19.44% | |||
| Gross Profit | 3,582.63% | -189.71% | |||
| SG&A Expenses | 3.02% | -28.99% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -22.54% | -22.83% | |||
| Operating Income | 528.50% | -210.42% | |||
| Income Before Tax | 530.52% | -334.24% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 526.98% | -334.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 526.98% | -334.24% | |||
| EBIT | 528.50% | -210.42% | |||
| EBITDA | 528.54% | -210.46% | |||
| EPS Basic | 528.89% | -333.00% | |||
| Normalized Basic EPS | 569.67% | -319.44% | |||
| EPS Diluted | 508.31% | -333.00% | |||
| Normalized Diluted EPS | 543.18% | -319.44% | |||
| Average Basic Shares Outstanding | -0.46% | 0.45% | |||
| Average Diluted Shares Outstanding | 5.49% | 0.45% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||